- Home
- PINE vs LXEO Comparison
PINE vs LXEO Comparison
Compare PINE & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PINE | LXEO |
|---|---|---|
| Founded | 2019 | 2017 |
| Country | United States | United States |
| Employees | 4 | N/A |
| Industry | Real Estate Investment Trusts | |
| Sector | Real Estate | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 334.6M | 368.3M |
| IPO Year | 2019 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PINE | LXEO |
|---|---|---|
| Price | $20.45 | $5.05 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | ★ $20.10 | $18.44 |
| AVG Volume (30 Days) | 195.5K | ★ 1.0M |
| Earning Date | 04-23-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.29% | N/A |
| EPS Growth | N/A | ★ 39.81 |
| EPS | ★ 0.06 | N/A |
| Revenue | ★ $60,532,000.00 | $654,000.00 |
| Revenue This Year | $18.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $337.50 | ★ N/A |
| Revenue Growth | ★ 15.90 | N/A |
| 52 Week Low | $13.10 | $3.60 |
| 52 Week High | $21.32 | $10.99 |
Technical Indicators
Market Signals| Indicator | PINE | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 55.36 | 52.17 |
| Support Level | $18.80 | $4.27 |
| Resistance Level | $21.06 | $5.34 |
| Average True Range (ATR) | 0.65 | 0.33 |
| MACD | -0.01 | 0.06 |
| Stochastic Oscillator | 67.20 | 59.05 |
Price Performance
Historical ComparisonAbout PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate investment trust (REIT) that owns and operates a high-quality portfolio of commercial net lease properties in the United States. The company's portfolio predominantly comprises single-tenant retail properties located in or near metropolitan statistical areas, or MSAs. It operates in two business segments: income properties, which derive maximum revenue, and commercial loans and investments.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.